BENGALURU (Reuters) - Indian drugmaker Eris Lifesciences Ltd said on Thursday it had bought nine dermatology brands from Dr. Reddy's Laboratories Ltd in a 2.75 billion rupees ($33.24 million) deal, to expand in the cosmetic dermatology business.
The deal, to be paid in cash, is expected to be completed on or before March 31, Eris said in a stock exchange filing.
Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands.
The deal comes two months after Eris said it would acquire a portfolio of dermatology brands from Glenmark Pharmaceuticals Ltd for 3.4 billion rupees to deepen its presence in the anti-fungal and anti-psoriasis segments.
Eris' shares were trading 1.4% lower as of 2:33 p.m. IST and were headed for a sixth straight session of losses. They have fallen 9.2% since announcing the deal with Glenmark.
($1 = 82.7250 Indian rupees)
Trading Strategies in Bandhan Bank, Eris Lifesciences by Mehul Kothari
Expensive deal valuations to hit Torrent Pharma's near-term earnings
AP government buys 19 new SUVs for CM Jagan Mohan Reddy's convoys
Major improvements in Andhra Pradesh's education, medical sectors: CM Reddy
Telangana polls are a do-or-die battle for a demoralised, divided Congress
myTVS selects Oracle cloud applications to improve business processes
Here is the reason why Disney+ Hotstar is ending its partnership with HBO
ED searches Franklin Templeton officials' homes for alleged irregularities
LinkedIn adds AI-powered writing suggestions, job descriptions to service
Indian industries stock up on coal to avoid shortages during summer
(Reporting by Yagnoseni Das and Hritam Mukherjee in Bengaluru; Editing by Rashmi Aich and Eileen Soreng)